header logo image


Page 1,060«..1020..1,0591,0601,0611,062..1,0701,080..»

Facing arthritis at a young age, Katie Dean turns to faith – The Simpsonian

March 3rd, 2017 2:44 am

by Madi Wilson, Features/Perspectives Editor March 2, 2017

Diagnosed with rheumatoid arthritis at age 11, sophomore Katie Deans childhood was different than most.

In 2008, Dean was playing basketball when she tripped and fell. Her left ankle quickly swelled up, making it extremely painful for her to walk on. She assumed it was a sprained ankle until her right hand started swelling up days later.

If you take a latex glove and blow it up, thats about the size [my right hand] was, Dean said. It was red and we decided that that is not good, so we went to the doctor.

Treating her swelling and redness as an infection, doctors soon realized they were wrong. Dean had developed more than just a swollen ankle and hand.

I began to get a rash around my waist, which they had never seen before, Dean said. So as a fifth-grader, thats kind of scary.

Dean was regularly in and out of the University of Iowa Childrens Hospital, and because her hand was extremely large, she had three or four different surgeries to extract pus.

Months later, doctors treated Dean with arthritis medicine, and it worked. They officially diagnosed her with RA and identified her rash as Sweets syndrome, a rare skin disease thats triggered by infections, illnesses or certain medications.

RA, an inflammatory disease in which the immune system attacks healthy joints and causes symptoms including pain, swelling, stiffness and loss of physical function, affected Deans ability to participate in sports.

I was in a lot of sports, she said. I was in basketball, volleyball and I did track. I continued to do those up until junior high because I had the mindset that I could do anything. But after, like, practices or games, I was always limping around, and I couldnt run. I realized that I couldnt do all of the things that I really wanted to do.

Although Deans experience was a physical setback, she didnt let her diagnosis negatively influence her academic efforts.

Im really school-focused, and so I knew that I could still do school no matter if I was in or out of the classroom. So it wasnt really a mental setback, but I did see myself as different for a really long time.

Deans experience was challenging, but there was one thing that helped her through it all: writing.

While I was sick I actually thought, you know, that God was punishing me for some reason, Dean said. I actually started writing about my condition and my faith, and I knew that I was obviously strong enough to get through it.

Since her diagnosis, Dean has written a few books titled A Step of Faith (2012), An Unforgettable Journey (2014), Healings, Hospitals, Happiness (2014) and is working on a novel called Bumps in the Road.

Through these novels, she hopes to help people with their tough experiences through forms of faith.

Dean also used prayer to guide her through her situation.

I guess what really helped was my mom, and I prayed every single day about it and every single night. And so that really had an impact on seeing God in a different way, she said.

Along with writing and prayer, Deans support system was, and still is, tremendous. Her parents were always by her side along with many of her friends who still ask how shes doing.

My friends were also very supportive, Dean said. They understand what I go through, and every time I see them they always ask, How are you doing? Is there anything that we need to do for you?

Deans arthritis is managed through her medication and a shot she takes every other week, but she occasionally has episodes of pain.

Every time I do have what I call flare, people are always aware and always try to help, she said.

One group thats made a huge impact on Deans life is Religious Life Community. After participating in a trip to Florida through RLC, she realized that God was calling her to be a minister.

Im really active in my home church, and so Ive always had that part of me, she said. Ive spoken in church a couple times, and I really enjoy speaking in front of people about God.

Majoring in religion with a double minor in theater and music, Deans plans are to go to seminary after she graduates. She hopes to use her experience to inspire others and teach them that faith can overcome any obstacle in life.

Read more:
Facing arthritis at a young age, Katie Dean turns to faith - The Simpsonian

Read More...

Keithley’s Korner: Big benefits from Stem Cell Therapy – Ruidoso News

March 3rd, 2017 2:43 am

Tim Keithley, Guest columnist 7:45 a.m. MT March 2, 2017

Tim Keithley(Photo: Courtesy)

Like a lot of folks who love to go skiing, play tennis, and enjoy the Ruidoso year-round beautiful weather, I became discouraged when my right knee went out climbing down a staircase recently.

I waited a few days figuring that it might heal like it always has done before. But this time the injury felt different and seemed to be getting worse.

Turns out you have a torn tendon in your right knee, Dr. Steven Rath of Fusion Medical Spa said on New Mexico in the Morning.

It obviously wasnt going to heal itself, so we had Tim come in and consider stem cell therapy, Dr. Rath said. It turns out that we were able to help his body heal itself without putting him through painful knee surgery.

Within a day after the procedure this week, the knee was sore from having the shots injected right into the tendon, but the regular pain had subsided. It made me a believer in the stem cell therapy Dr. Rath has been talking about on the radio for some time.

Heres a simple explanation of the procedure: Dr. Rath draws your own blood, then separates out the healing platelets through a spinning process, then injects those back into your body to the specific area that needs healing.

Stem cell therapy is nothing new, but its still considered an alternative form of treatment and an experiment, Dr. Rath said. Part of the reason why insurance companies dont cover the procedure has to do with the fact that medical companies prefer patients have surgery when it may not be necessary.

There may be patients out there who definitely need surgery, but providing this procedure has kept many of my patients from having to go under the knife.

Having had the procedure done on my knee this week, I can testify that it works and has given me a new hope that soon Ill be back on the slopes and the tennis court without having the ordeal of potential knee surgery.

Thus far in my practice, stem cell therapy has helped many people in your same situation, Dr. Rath said.

Tim Keithley is the host of the New Mexico in the Morning radio show Monday through Friday, 9 to 10 a.m., on KRUI 1490 AM, KWMW 105.1 FM and 99.1 FM or live streaming at mtdradio.com.

Read or Share this story: http://r-news.co/2lDmO8k

More here:
Keithley's Korner: Big benefits from Stem Cell Therapy - Ruidoso News

Read More...

International Stem Cell Corporation Announces Third Patient with Parkinson’s Disease in Phase I Clinical Trial – GlobeNewswire (press release)

March 2nd, 2017 1:54 am

February 28, 2017 08:30 ET | Source: International Stem Cell Corporation

CARLSBAD, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced the third patient in the clinical trial for Parkinson's Disease was successfully transplanted with ISC-hpNSCcells and is already discharged from the Royal Melbourne Hospital (RMH). The operation was successfully performed without complications by the team of the RMH neurosurgeons.

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO commented: "The third operation went according to plan and we are on track to dosing all of our clinical trial participants in 2017. We have enrolled the fourth patient and we expect to perform the surgery in March. No test article related adverse events have been recorded for any of the patients transplanted in 2016.

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC, intracranially transplanted into patients with moderate to severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSCwill be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

About Parkinson's disease

Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.

Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.

About ISC-hpNSC

International Stem Cell Corporation's proprietary ISC-hpNSCconsists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSCis a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC. ISC-hpNSCprovides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSCis safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSCmay have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of human pluripotent stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit:www.facebook.com/InternationalStemCellCorporationandwww.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected results and timing of clinical studies, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Related Articles

International Stem Cell Corporation

Carlsbad, California, UNITED STATES

International Stem Cell Corporation Logo

LOGO URL | Copy the link below

Formats available:

See more here:
International Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial - GlobeNewswire (press release)

Read More...

Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity – Medical Xpress

March 2nd, 2017 1:54 am

March 1, 2017 Neural progenitor cells (green) in the lateral ganglionic eminence (LGE), the region in the developing brain that produces the majority of adult neural stem cells. Credit: Sven Falk

Neurodegenerative diseases such as Alzheimer's or Parkinson's, but also strokes or other types of traumatic brain damage, result in the death of nerve cells in the brain. Since the mammalian brain is capable of replacing nerve cells only in certain restricted regions, such nerve-cell loss is in most cases permanent. Similarly, the capacity to form new nerve cells in the mature brain is limited to specific areas. The cells responsible for neurogenesis in the mature brain are called adult neural stem cells, but little is known about their developmental origins. Now an international research collaboration led by Magdalena Gtz, Professor of Physiological Genomics at LMU's Biomedical Center and Director of the Institute for Stem Cell Research at the Helmholtz Zentrum Munich, has demonstrated that the mode of division of stem cells has a profound influence on the numbers of adult neural stem cells formed during embryonic development.

The new findings appear in the journal Neuron.

Neural cells develop from progenitors called neural stem cells, which are produced in large numbers during embryonic development. However, in the mature mammalian brain, very few of these progenitors survive as so-called adult neural stem cells capable of generating new nerve cells. In order to determine what enables these cells to retain their stem-cell character into adulthood, Gtz and her colleagues took a closer look at neural stem cells in the developing mouse embryo called radial glia cells (RGCs). RGCs form long processes that span the apicobasal axis of the neuroepithelium and their nuclei come to lie close to the apical surface which faces a fluid-filled cavity known as the ventricle. When RGCs divide, some of the daughter cells again are RGCs, i.e. the RGC self-renews. These cells that retain the self-renewing capacity, a characteristic of stem cells, are the source of the adult neural stem cells found in a specific region of the developing brain called the lateral ganglionic eminence, which forms the lateral wall of the ventricle in the adult brain. The nerve cells derived from the adult neural stem cells subsequently migrate into the olfactory bulb, one of the regions in which new nerve cells are integrated in the mature brain.

"We have now shown that the orientation of the plane of division of embryonic progenitor cells has a major impact on the production of adult neural stem cells," Gtz says. The plane of cleavage during cell division determines which parts of the cytoplasm are inherited by the two daughter cells. Most of the RGCs in the lateral ganglionic eminence were found to divide along a plane that is approximately vertical (at an angle of 60-90) to the apical cell surface. However, when the researchers genetically randomized the orientation of the cleavage plane such that the frequency of oblique or horizontal divisions was increased the number of adult neural stem cells generated was significantly reduced. Hence the orientation of the cleavage plane of RGCs is a crucial factor that affects the number of adult stem cells. However, timing also plays a crucial role. Adult neural stem cells are produced only during a specific, temporally and regionally restricted phase in embryonic development. Genetic randomization of the cleavage plane progenitor cells in the post-natal mouse brain proved to have no effect on the number of adult stem cells.

The total number of adult neural stem cells produced is a crucial determinant of the brain's capacity for repair and regeneration, because each of these cells can generate only a limited number of new nerve cells. "With a better understanding of how the formation of adult neural stem cells is regulated, we could look for ways of ensuring that other embryonic neural stem cells maintain this capacity, and perhaps even persuade other cell types to do so. Our new results represent an important step toward this goal," says Sven Falk, first author of the new study. The researchers hope that their findings will open up new approaches to the therapy of neurodegenerative diseases.

Explore further: Specific roles of adult neural stem cells may be determined before birth

More information: Sven Falk et al. Time-Specific Effects of Spindle Positioning on Embryonic Progenitor Pool Composition and Adult Neural Stem Cell Seeding, Neuron (2017). DOI: 10.1016/j.neuron.2017.02.009

Adult neural stem cells, which are commonly thought of as having the ability to develop into many type of brain cells, are in reality pre-programmed before birth to make very specific types of neurons, at least in mice, according ...

Stem cells in the brain can produce neurons and are consequently seen as a hope for treatment. A team of researchers from the Helmholtz Zentrum Mnchen and Ludwig-Maximilians-Universitt Mnchen (LMU) has now discovered ...

Prof. Fiona Doetsch's research team at the Biozentrum, University of Basel, has discovered that the choroid plexus, a largely ignored structure in the brain that produces the cerebrospinal fluid, is an important regulator ...

Blood vessels play a vital role in stem cell reproduction, enabling the brain to grow and develop in the womb, reveals new UCL research in mice.

A wireless arm patch may be a promising new treatment for migraine headaches, researchers report.

Scientists have used a unique computational technique that sifts through big data to identify a subset of concussion patients with normal brain scans, who may deteriorate months after diagnosis and develop confusion, personality ...

(HealthDay)Multiple sclerosis (MS) is more likely to progress to advanced disease among patients who suffer from fatigue and limited use of their legs, new research suggests.

How does consciousness arise? Researchers suspect that the answer to this question lies in the connections between neurons. Unfortunately, however, little is known about the wiring of the brain. This is due also to a problem ...

(Medical Xpress)A team of researchers with the Allen Institute for Brain Science led by Christof Koch gave a presentation recently at the Brain Research through Advancing Innovative Neurotechnologies meeting outlining ...

Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bioassay grown on multi-electrode arrays capable of detecting the biological activity of Clostridium botulinum ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity - Medical Xpress

Read More...

Stem cells make potential drug side effects personal – New Atlas

March 2nd, 2017 1:54 am

Researchers in Singapore have developed a wayto use patients'stem cells to see whether acancerdrug is safe for them(Credit: Institute of Bioengineering and Nanotechnology)

In a promising development that strengthens the case for personalized cancer care, scientists in Singapore have demonstrated the possibility of predicting the potential for an individual to have adverse side effects to different drugs by first testing them on stem cells made from the patient's own blood.

For doctors, prescribing cancer drugs is often a hit-or-miss affair. Even though a therapy has been approved by a regulatory body, there's still a chance someone could have a bad reaction and develop severe side effects, such as liver failure. Such cases are termed idiosyncratic, as opposed to intrinsic, which can be predicted and therefore avoided. As the name suggests, with idiosyncratic drug-induced liver injury (DILI) it is difficult to predict a drug's side effects on an individual patient in advance, which could lead to hospitalization and even death.

Pazopanib is a drug commonly prescribed for advanced kidney cancer. However, like many cancer therapies, it doesn't work for everyone and has been known to cause liver damage in patients who react badly to it. In the study, researchers at the Institute of Bioengineering and Nanotechnology (IBN) and the National Cancer Centre Singapore (NCCS) used induced pluripotent stem cells (iPSCs) adult cells that have been genetically reprogrammed into an embryonic cell-like state to create liver cells from the blood of five kidney cancer patients, three of whom were known to have adverse reactions to the cancer drug. The goal was to find out if they could reproduce adverse reactions to pazopanib in these cells.

When these newly created liver cells were exposed to the drug, the researchers found that not only were the results similar to post-treatment data derived from liver biopsies, they were also able to gain a better understanding of how the drug caused liver damage, which was previously unknown to doctors. This is the first time that a study has demonstrated the ability of genetically matched iPSCs to model drug-induced idiosyncratic side effects, which may result from predisposing genetic factors that an individual patient might have. What the results make clear is that idiosyncratic DILI has multiple causative factors and cannot be attributed to a single risk factor.

"Our hypothesis was that liver cells made from the individual's blood might show similar sensitivity or resistance to pazopanib," says study author Min-Han Tan, a medical oncologist. "This study is the first proof-of-concept that our approach can predict drug-induced liver damage for an individual. Importantly, we were able to figure out how the drug works from the way they react to the liver cells, which was unknown to doctors, even after many years of using this drug."

Among the findings was the identification of the role altered iron metabolism could play in pazopanib-induced liver injury. NCCS consultant Ravindran Kanesvaran believes understanding the mechanism of this particular side effect of the drug could lead to ways to overcome it.

While the study's small sample size might bring with it statistical limitations, the researchers, who are currently planning formal clinical trials, believe these findings could provide impetus for using patient-specific stem cells to screen for idiosyncratic drug reactions, especially since there is currently no suitable test for these cases.

Further studies on drugs that affect other organs are in the pipeline, and the researchers say in the future it might be possible to predict a patient's reaction to a drug by screening personalized stem cells comprising a range of liver, lung, kidney and heart cells.

Apart from benefitting patients, such a procedure could also help keep promising therapies on the market. Presently, phase III clinical trials (i.e. the stage that assesses the effectiveness of a new therapy) involve patient groups comprising between 300 and 3,000 people. And because they are so rare, it is easy for cases of idioscyncratic DILI to slip under the radar during these trials. As the study's authors note, this results in "considerable morbidity, mortality, treatment dose attenuation and interruption," which often leads to drugs being pulled off the market, depriving patients who do not have such reactions of what could be a promising treatment for them.

"Currently, new drugs are tested for toxicity using generic liver cells, which cannot model patient-specific reaction," says team leader and principal research scientist Hanry Yu. "By personalizing liver cells from the blood of individual patients, we can help doctors to prescribe safer and more effective therapies."

The paper was published in Scientific Reports.

See the original post here:
Stem cells make potential drug side effects personal - New Atlas

Read More...

Creo Medical Group joins European stem-cell cancer project … – DIGITALLOOK

March 2nd, 2017 1:54 am

Medical device company Creo Medical Group said it was taking part in a European programme researching a stem-cell cancer treatment for brain tumours.

The AIM-listed company is to join the Semiconductor-based Ultrawideband Micromanipulation of Cancer Stem Cells (SUMCASTEC) H2020 FET open research programme, led by the XLIM Research Institute at the University of Limoges in France.

Creo will be one of six European partners in a consortium of neurologists, microbiologists and engineers, who are aiming to develop a "micro-optofluidic lab-on-chip platform that deploys semi-conductor technology to neutralize cancer stem cells with electromagnetic waves".

The consortium was awarded a 4m (3.4m) grant, and 530,000 of which will be allocated to Creo, which lead on the development of the cell neutralisation aspect of the programme with a view to potentially commercialise the lab-on-chip platform.

Creo said that certain aspects of the project are closely related to the work it is already doing for the treatment of lung tumours.

SUMCASTEC is based on the isolation and neutralisation of cancer cells associated with some of the most aggressive brain tumours, specifically Glioblastoma Multiforme and Medulloblastoma.

Brain cancers are a leading cause of death in Europe, as according to the World Health Organisation 57,000 new cases and 45,000 deaths were reported in Europe in 2012.

Chris Hancock, chief technology officer of Creo, said: "This grant recognises the potential of Creo Medical's innovative ablation technology and its potential application in new and challenging fields. This new system has the potential to provide a new treatment option for some of the most aggressive brain tumours."

Arnaud Pothier, main project leader and senior researcher at Limoges University, added: "Creo's development expertise and growing commercial infrastructure makes them an ideal consortium partner to bring the lab-on-chip into human use and then to market."

Shares in Creo Medical Group were up 0.77% to 92.2p at 1524 GMT.

Follow this link:
Creo Medical Group joins European stem-cell cancer project ... - DIGITALLOOK

Read More...

New Retinal Device May Give Hope To The Blind – CBS Chicago

March 2nd, 2017 1:53 am

March 1, 2017 10:08 PM By Marissa Bailey

(CBS) A blind man can see light for the first time in 20 years, all thanks to a revolutionary device being researched right here at the University of Illinois-Chicago.

CBS 2s Marissa Bailey explains how it could change the lives of the blind.

This is no regular eye doctors appointment.

This is Bob Selbys first check-up since Dr. Jennifer Lim at UIC implanted the groundbreaking retinal device called the Argus II.

Ive been legally blind my whole life, really, Selby says.

The 55-year-old was born with Retinitis Pigmentosa. He was diagnosed in his 20s and completely blind by 35.

The part of the retina that doesnt work is the part of the retina that gathers the light. The photoreceptors are dead but the inner retina works, Dr. Lim explains.

Selbys device was implanted in October and thenturned on in November. Thats when he saw light flashes for the first time in more than 20 years.

Now he can see edge and contrast effects and can pick people out, but before he didnt know where they were unless they would say something, Lim says.

Heres how the device works: The lens on Selbys glasses transmits an image through a video processor box. It wirelessly sends instructions to the implant on Selbys eye. Those messages stimulate Selbys retina to send signals along the optic nerve to his brain, which allows him to see.

Within minutes of turning on the device, Selby was navigating unfamiliar hallways by himself.

Wow! Ive never been so happy to see a wall before, he said that day.

Selby calls the technology a game-changer.

For patients, its huge.To be able to see light and then not only to see the light but to have the light mean something, Lim adds.

Selby practices with his new found sight a couple of hours a day.

He says if he can see light flashes now, this may be the beginning of the end for blindness.

Imagine what they could do in five to 10 years, he says.

Selby is one of only 60 people in the world with this FDA-approved retinal implant. UIC is one of 13 sites in the U.S. where its being used.

The Argus II is now being studied in Europe for people with macular degeneration.

Marissa Bailey is the weekend anchor of the CBS 2 Chicago morning newscasts and a general assignment reporter for the station. Marissa joined the station in March 2012 as a reporter and was promoted to anchor the stations Saturday and Sunday...

Link:
New Retinal Device May Give Hope To The Blind - CBS Chicago

Read More...

Beware Of This ‘Thief Of Sight’ That Can Gradually Cause Blindness – malaysiandigest.com

March 2nd, 2017 1:53 am

Details Published on Thursday, 02 March 2017 08:32 Written by Thorsten Marquardt

Glaucoma, the silent thief of sight, is a group of diseases caused by damage to the optic nerve in the eye.

Without any warning signs or symptoms it will slowly take away the affected persons eye sight and can even cause blindness if not treated appropriately.

Tanaletchimy Rajaratnam, 63, felt completely healthy and had no symptoms at the time she was diagnosed with high eye pressure during a routine eye screening in the UK.

With high eye pressure being the number one cause for glaucoma, she decided to start the treatment right away.

Taking the risk seriously, going for regular checkups and starting with the treatment early enough helped keeping the diseases progress at bay.

This is the reason why today, 10 years after she was diagnosed with glaucoma, her eye sight has not been significantly affected.

Without early detection and swift action, this could have played out very differently.

Another patients son, Mr Wong, told MalaysianDigest, at the Tun Hussein Onn National Eye Hospital that his 75 year old father had been affected by glaucoma for a long time without even noticing it.

Only after the disease had already severely damaged his eyes and even started to cause pain, he finally consulted a doctor.

Without appropriate treatment, he is now at risk of going blind.

Before being diagnosed with the disease, like most people, both patients werent even aware of its existence. Like many other glaucoma patients in Malaysia, Wong andTanaletchimy accounts of the onset of the disease highlights the invisible nature of this condition until it is too late.

The Malaysia Glaucoma Society had produced the following public announcement about this disease a few years back to create awareness of this 'silent thief of sight'.

The World Glaucoma Week held in March each year takes place on 12 to 18 March 2017 and to help raise awareness, we have decided to highlight this often 'invisible' illness and look at a local eye hospital's role in helping glaucoma patients.

The Silent Thief Of Sight

If the optic nerve that connects the eye to the brain is too damaged, it will not be able to send an accurate and complete picture to the brain causing reduced eye sight.

This results in people having blurry vision and a restricted field of view or missing objects in their view.

Glaucoma usually comes without any symptoms and often stays undetected for a long time.

Not always, but very often, glaucoma is caused by high eye pressure damaging the optic nerves.

To be more specific, glaucoma usually develops when the production of an eye fluid called aqueous humour either increases or fails to drain properly.

This causes the pressure in the eye to rise which can damage the fibres in the optic nerve resulting in interruptions to the transmission of visual messages to the brain.

Eye drops are used to reduce the eye pressure and keep it stable to prevent further damage to the nerves.

Eye pressure is the main cause for glaucoma, but not required for its development.

People with normal eye pressure can still be affected, while people with high eye pressure are more likely to be at risk but dont necessarily develop the disease.

It is estimated that half of the people affected by glaucoma do not know that they have it, which is a serious problem because if left undetected and untreated it can lead to blindness.

According to the World Health Organization, Glaucoma is the second most common cause of blindness worldwide and it is estimated that 4.5 million persons globally are blind due to glaucoma.

If left untreated, most types of glaucoma progress (without warning nor obvious symptoms to the patient) towards gradually worsening visual damage and may lead to blindness, states the World Glaucoma Association.

Since there is no cure, the damage caused to the optic nerves and the reduced eye sight are irreversible, therefore it is important to detect it early.

There is no cure for glaucoma as yet, and vision loss is irreversible. However medication or surgery (conventional or laser) can halt or slow-down any further vision loss. Therefore, early detection is essential to limiting visual impairment and preventing the progression towards severe visual handicap or blindness, states the World Glaucoma Association.

Everybody Is At Risk Of Glaucoma

Datuk Dr. Linda Teoh, a full time consultant ophthalmologist and glaucoma specialist at the Tun Hussein Onn National Eye Hospital (THONEH), told MalaysianDigest that everybody can be affected by glaucoma.

There are certain risk factors, like for example high eye pressure and a family history, but the disease can affect anyone.

It is not just about the eye pressure. The eye pressure might be normal but the person can still develop glaucoma. There can also be people with high eye pressure but no glaucoma. Too many people look only at the eye pressure, she said.

People with high eye pressure are at a much higher risk of getting glaucoma and it is generally assumed that people with a family history of glaucoma already have a 1 in 4 chance of developing the disease.

There are, however, many other factors that come into play.

Everybody is potentially at risk of developing glaucoma, but there are certain risk factors that increase the likelihood.

People above the age of 60, people with diabetes, people who have used steroids for a long period of time and people with physical eye injuries are also at a higher risk.

Some ethnicities are more prone to the disease than others.

The Glaucoma Research Foundation found that African Americans are more likely to be affected by glaucoma than Caucasians.

The ingredients of certain weight loss appetite suppressant pills are also linked to an increased risk.

In Malaysia around 1.8 percent of the population is affected by glaucoma and, according to surveys, only 21 percent of the population are even aware of the disease.

Since glaucoma is very unpredictable, can affect anyone and comes without warning, routine eye checkups, measuring eye pressure and conducting visual field tests are crucial in detecting and treating the disease early enough to avoid major irreversible damage to the eye sight.

Education And Cooperation Between Doctor And Patient Are The Key To A Successful Treatment

When it comes to treating glaucoma, it is very important that the patient and the doctor are on the same page.

Since glaucoma is a disease that continuously gets worse while causing irreversible damage, regular checkups and adjustments to the treatment are very important.

In order to keep the disease from progressing, it is required to keep the eye pressure low and stable.

Datuk Dr. Linda Teoh, a full time consultant ophthalmologist and glaucoma specialist at the Tun Hussein Onn National Eye Hospital (THONEH)Glaucoma is actually a group of diseases causing damage to the optic nerve of the eye. By controlling the eye pressure, the drops can slow down the progress of glaucoma, Dr. Linda explained.

I think what is important is education. Patients should know the nature of the disease and understand how it progresses.

Despite the aggressive nature of the disease and lack of cure, it is possible to prevent the loss of eye sight through appropriate treatment.

This, however, can be costly, time consuming and requires the patients to actively take an interest in informing themselves about the disease and be compliant with their medication.

Dr. Linda thinks that a lack of education and knowledge about the disease leads many patients to be neglectful and hamper the effectiveness of the treatment.

They feel there is no improvement in spike of treatment. They fail to understand the nature of the disease. Then they blame the doctor if they dont get better. They always want to improve, but what they dont understand is that Glaucoma cannot be improved; its progress can only be slowed down. What they need is education, she said.

In order to successfully treat the disease and prevent it from progressing, patients have to go for regular checkups, use the prescribed medicine correctly, meet doctors regularly to adjust the treatment based on changing conditions and undergo surgery (to control the eye pressure) if the necessity arises.

The drops used to reduce the eye pressure, for example, have to be adjusted regularly depending on whether the eye pressure are effectively controlled in order to avoid fluctuations that damage the optic nerve further.

Dr. Linda opined that patients who are either too uninformed and ignorant about the disease or dont trust the doctors are more likely to fail at properly treating the disease.

Tanaletchimy, who managed to slow down the progress of the disease by being very proactive and engaged with her doctors also sees cooperation between doctors and patients as the most important factor.

Just listen to what the specialists have to say. They are the experts. You must have confidence in the doctor and just follow what the doctor suggests, she said.

According to Dr. Linda, education, cooperation with the doctor, early detection and early treatment are the most important factors in successfully treating glaucoma.

In conjunction with the World Glaucoma Week 2017 starting from March 12, the Tun Hussein Onn National Eye Hospital (THONEH) will be hosting an open day on 22 March 2017 (Wednesday).

There will also be a presentation ceremony and a series of programmes including an eye health talk open to the public. For further information, contact THONEH at 603-7718 1588 or email This email address is being protected from spambots. You need JavaScript enabled to view it..

-mD

Originally posted here:
Beware Of This 'Thief Of Sight' That Can Gradually Cause Blindness - malaysiandigest.com

Read More...

‘Treasure map’ identifies first genetic clues to form of blindness – Blue Mountains Gazette

March 2nd, 2017 1:53 am

27 Feb 2017, 6:11 p.m.

Researchers have identified genetic clues which could reveal a person's risk of going blind.

Tom Doumani thought something was up when he started having trouble reading street signs while driving. Letters seemed to be missing and, if the street name was an unfamiliar one, he had no way of guessing what it might be.

It was enough to prompt him to go and get his eyes tested. However the results showed his long distance vision was fine.

Unconvinced all was as it should be, he mentioned it to his GP who referred him to an eye specialist. This time the tests picked it up. Dr Doumani had the rare and rather awkwardly named Macular Telangiectasia type 2.

Like many rare conditions, little is known about what causes "MacTel 2", which in scientific circles is known as idiopathic juxtafoveal telangiectasia. Idiopathic meaning "of unknown cause".

However that may have changed, thanks to research led by Melbourne scientists which has found "a treasure map" revealing the location of the genetic triggers behind this little-understood form of blindness.

Outlined in the journal Nature Genetics, it is the first clue as to what causes MacTel 2, an incurable and untreatable degenerative disease which affects people from age 40 upwards.

The condition is characterised by an abnormal growth of blood vessels in the macula. Patients lose their central vision and tasks such as driving and reading can become impossible.

The international study was led by Walter and Eliza Hall Institute of Medical Research scientists Melanie Bahlo and Thomas Scerri.

The research team, including scientists in New York and London, analysed more than 6 million genetic markers in the genome of patients with the condition and compared them to those without.

Among the 476 people diagnosed with MacTel 2, genetic similarities were found in five key regions of the genome.

Curiously four of the five regions are associated with a person's metabolism. Those with MacTel 2 recorded lower levels of the basic amino acids glycine and serine.

"That was a bit of a surprise to say the least," Professor Bahlo said.

The fifth region identified, in what Professor Bahlo has described as "our treasure map", is tied to the size of retinal blood vessels.

"This is the first time we have been able to say with certainty that this is a genetic condition," she said. "And the map tells us where to 'keep digging' in order to discover the specific genes implicated in MacTel 2."

Identifying the specific genes would lead to improved diagnostic testing for the disease which is notoriously difficult to identify and also developing ways to prevent or stop its progression.

Diagnosed in 2012 at the age of 61, retired corporate banker Tom Doumaniwas among theMelbourne participants, sourced through Centre for Eye Research Australia. Heknows that while he may not benefit directly from participating in the study, he is contributing to the global search for a cause or cure.

"To help advance the knowledge, that's what appealed to me in taking part," he said. "I had no hesitation in participating."

The story 'Treasure map' identifies first genetic clues to form of blindness first appeared on The Sydney Morning Herald.

See more here:
'Treasure map' identifies first genetic clues to form of blindness - Blue Mountains Gazette

Read More...

Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima – Yahoo Finance

March 2nd, 2017 1:53 am

HAMILTON, N.J., March 1, 2017 /PRNewswire/ -- Genesis Biotechnology Group (GBG), a consortium of an integrated group of biotechnology and research companies, announced that it has expanded its drug development services by the acquisition of PharmOptima.

PharmOptima, a preclinical Contract Research Organization (CRO) company, joins Invivotek and Venenum Biodesign in the existing drug development segment of GBG. This acquisition expands GBG's catalogue of available services, while providing the same high quality service each company's clients have grown to expect. Effective with this acquisition, GBG will provide new and existing customers with the added value of a single point-of-contact for the efficient development and coordination of their unique preclinical drug development program.

According to Dr. Eli Mordechai, GBG's CEO, "This partnership brings together highly complementary services of three companies creating a dynamic and efficient enterprise that will enable clients to have access to a comprehensive portfolio of bio-analytical and in vivo services in multiple therapeutic areas." This spirit of collaboration was supported by PharmOptima's CEO, Steven Weber, who stated, "PharmOptima is excited to become a part of the GBG consortium that will have the synergistic effect of expanding both the breadth and depth of expertise in advancing the drug development activities of our clients and partners."

About GBG

GBG is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. Through the consolidation of research activities, and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG will be better positioned to create and sustain complex research platforms in drug discovery and the design of surrogate biomarkers for chronic diseases.

About PharmOptima

Since 2003, PharmOptima has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development. PharmOptima's in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology.It provides liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines.Its biochemistry expertise allows them to assess the role of biomarkers in numerous disease models. PharmOptima's biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression. Its expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.

About Invivotek

Invivotek offers both custom and standard preclinical services for drug discovery and development programs for their clients. Services offered by Invivotek include studies in animal models and bioassays to test compounds related to immunology and inflammation, oncology, metabolic and cardiovascular diseases.Invivotek's in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as by functional assays with primary cell cultures. These assays provide tools to study the mechanisms of action of various test therapeutics or potential target genes and to explore biomarkers for drug efficacy. Invivotek's experience across multiple therapeutic areas and its efficient project management, positions the company as a leading provider of preclinical in vivo services.

About Venenum Biodesign

Venenum Biodesign (Venenum) focuses on the identification of potentially therapeutic compounds starting with ultra-high throughput screening (UHTS) against their proprietary 5.5 million ECLiPS compound collection. Compounds identified by UHTS are advanced into preclinical drug candidates using in-house medicinal chemistry, crystallography and molecular modeling. Venenum's drug discovery biology capabilities are supported by expertise in in vitro andcell-based assay development, protein expression and purification, and assay reagent generation. Venenum has extensive experience working in a wide variety of therapeutic areas with conventional target classes, such as G protein-coupled receptors (GPCRs), enzymes, nuclear hormone receptors (NHRs), as well as with protein-protein or protein-DNA interactions.

Read More

Go here to see the original:
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima - Yahoo Finance

Read More...

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events – Market Exclusive

March 2nd, 2017 1:53 am
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events
Market Exclusive
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over ...
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017Business Wire (press release)
Puma Biotechnology Reports Fourth Quarter and Full Year 2016 ...Yahoo Finance
Puma Biotechnology Inc (NYSE:PBYI) Registers a Net Consolidated EPS Of $-7.4483Equities Focus
NewsDen
all 6 news articles »

Read more:
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events - Market Exclusive

Read More...

BRIEF-Puma Biotechnology provides update on review of marketing authorisation application for PB272 – Reuters

March 2nd, 2017 1:53 am

March 1 Puma Biotechnology Inc:

* Puma Biotechnology provides update on review of marketing authorisation application for PB272

* Puma Biotechnology Inc - company plans to modify summary of product characteristics in its marketing authorisation application

* Puma Biotechnology-plans to modify summary of product characteristics based on meeting with rapporteur, co-rapporteur, review team members, EMA

* Puma Biotechnology - proposed summary of product characteristics will continue to include both hormone receptor positive, hormone receptor negative patients

* Puma-Will be revising proposed smpc for neratinib to restrict intended population to patients within a year after completion of Adjuvant Trastuzumab Therapy

* Puma-Committee for medicinal products for human use continuing to review co's maa and has not yet made a final decision to recommend approval of drug Source text for Eikon: Further company coverage:

BRUSSELS, March 2 Anheuser-Busch InBev, the world's largest brewer, raised its forecast for savings from its near $100 billion takeover of SABMiller after weaker than expected earnings as beer sales suffered in Brazil.

TOKYO, March 2 Japan's Nikkei share average hit a 14-month peak on Thursday as the yen weakened against the dollar on heightened expectations for the Federal Reserve to raise interest rates this month and after Wall Street soared to record highs.

* Acquired privately held Ontology Systems for a total consideration of US$7.6 million, net of cash

More:
BRIEF-Puma Biotechnology provides update on review of marketing authorisation application for PB272 - Reuters

Read More...

New implant could improve treatment of thumb arthritis – Irish Times

March 2nd, 2017 1:51 am

Dr Brendan Boland (left) and Gerry Clarke of Loci Orthopaedics

InDX, a new thumb implant from Galway-based medical devices start-up Loci Orthopaedics, has the potential to completely disrupt how painful thumb joint arthritis is treated, according to its founders Dr Brendan Boland and engineer Gerry Clarke.

The thumb base joint is one of the most remarkably complex but beautifully elegant joints in the body, but when a problem develops, the current treatment options are not great, Boland says. Some surgeons take out a bone. Others fuse the joint. Joint implants similar to those used in hip arthritis are also used but they have an unacceptably high failure rate because of the complexity of the joint. What makes InDX different is that it is the only implant that allows the joint to move the same way as a healthy joint moves. It totally reproduces the natural movement, allowing patients to return to full functionality in a matter of weeks.

The thumb base joint is a small but highly mobile structure located just above the skin crease of the wrist. The bones within it can move in different directions and this remarkable flexibility is both its strength and weakness. Over time the joint can deteriorate, leading to painful arthritis. One in 10 of the general population and one in three women over 55 suffer from the condition.

Boland says the current value of the treatment market for thumb base arthritis in the US and EU combined is an estimated $600 million per year. However, due to ageing populations, this is expected to grow to $1.2 billion over the next 15 years.

Severe pain is usually the main symptom of this problem, with people unable to turn a key, do up buttons or even write, he says. Surgeons generally try to take out the trapezium bone to stop the bones rubbing together and hence remove the pain. However, this causes the hand to become significantly weaker, as it changes the anatomy of the joint so much. Some surgeons will harvest a tendon from the forearm to try and support and reconstruct the joint, but this hasnt been found to be clinically beneficial. Fusing is another option but function can be significantly impaired, while existing implants have a failure rate of up to 40 per cent.

Loci Orthopaedics is based at the Business Innovation Centre in NUIG Galway. The company expects to create eight direct jobs over the next three years, while outsourced manufacturing of the titanium implant will also take place in Galway. The company is now looking to raise 2.5 million to fund further development, compliance and distribution. The first clinical trial of InDX in Europe will take place in just over a year and Boland says the device should go on sale in the US in about in 18 months.

InDX has been developed in conjunction with three eminent international hand surgeons and their support for the product means the medical community is already aware of the implant. We are in the fortunate position of having end users waiting, Boland says.

Read more from the original source:
New implant could improve treatment of thumb arthritis - Irish Times

Read More...

Feline arthritis: How to spot the signs – Hamilton Spectator

March 2nd, 2017 1:51 am

The veterinarians at Village Cat Clinic in Ancaster can help you tell the difference between natural aging and arthritis in your feline and provide pain management techniques to keep your cat comfortable in their senior years.

Arthritis is common in older pets, but they cant speak up when the pain in their joints and spine becomes unbearable. There are signs that you can watch for, and indicators that they are suffering from discomfort beyond the natural aging process.

Activity

If you notice a significant decrease in your cats activity level or notice that they are sleeping more than they did when they were younger, then your cat may be experiencing arthritis pain.

Lameness

If your feline shows stiffness when they get up after a nap that lessens once they get mobile, it is a sign your pet may suffer from arthritis.

Mood changes

When were in pain, we often become short-tempered. Animals can react the same way, and may growl or bite when they are handled because it is painful for them to be picked up or patted.

Excessive licking, chewing or biting

Cats may become fixated on painful joints and lick, chew or bite the affected area, causing it to become inflamed or raw.

Agility

With aging comes less agility, but if you notice your cat has great difficulty accomplishing small feats such as jumping on or off your bed or a chair, have a vet check for arthritis.

Village Cat Clinic has several multi-modal pain medications that offer safe and effective pain management for your aging pet and their individual needs. They can also suggest modifications you can make in the home to help keep your senior cat more comfortable and improve their quality of life, such as assisted devices like stools to aid them on and off a bed or chair.

Other environmental improvements can help, such as diet changes, weight management and physical activity. It is important to provide comfortable, warm sleeping areas for your cat and easy access to food, water and a litter box.

For more information about caring for your arthritic feline, contact the Village Cat Clinic by email at reception@villagecatclinic.ca or call 905-304-7877.

See the article here:
Feline arthritis: How to spot the signs - Hamilton Spectator

Read More...

Alabama Lions Sight takes services on the road with state’s first Mobile Eye and Vision Clinic – Alabama NewsCenter

March 1st, 2017 7:51 am

For many low-income residents across rural Alabama, the everyday world is a dim and blurry place.

Durden Dean, executive director, Alabama Lions Sight Conservation Association, said 250,000 to 300,000 people statewide cant afford insurance, dont qualify for Medicaid or are not old enough for Medicare. Senior citizens are the fastest-growing population in Alabama, yet they are the most underserved, especially when it comes to receiving necessary eye care, he said.

To help meet this need, Alabama Lions Sight unveiled a Mobile Eye and Vision Clinic in Birmingham on Feb. 24. Since 1944, Alabama Lions Sight has provided services to more than 350,000 people and has worked to save sight through research, education, detection and treatment.

Many people in rural communities cant afford eye care, or they dont have transportation to an area where they can get it, so they basically do without, Dean said. We feel like we have an obligation to offer eye care to those communities where people cant get it.

Alabama Lions Sight fufills a vision of community with mobile eye clinic from Alabama NewsCenter on Vimeo.

The first of its kind in the state, the fully equipped clinic on wheels provides comprehensive eye care to senior citizens and indigent people in Alabamas Black Belt and Appalachian regions.

Services include eye exams, case management and patient care coordination, free transportation to prescribed treatment and follow-up support. Patients will be checked for diseases, such as cataracts, glaucoma and diabetes. Those needing glasses will either receive a prescription or have the opportunity to choose from frames available through the clinic.

We see people who havent had eye care in a while, said Dr. Kent Daum, director of the traveling clinic and retired UAB professor of optometry. We see people who have eye infections, glaucoma or diabetes, or who need glasses, just like other clinics. The difference is the conditions are very concentrated because people havent been treated for a long time.

The new clinic has been on the road since Feb. 12, but Alabama Sight actually began piloting its mobile program last year. Since then, Daum has seen about 1,500 patients at 17 healthcare clinics in 14 counties.

The clinic has made stops at healthcare centers in Hale, Marengo, Sumter, Perry, Pickens, Dallas, Wilcox, Lowndes, Autauga, Elmore, Chilton, Coosa, Greene and Montgomery counties. Some of the many communities that have received visits are Carrollton, Eutaw, Greensboro, Pineapple, Selma, Hayneville and Eclectic.

The Alabama Lions first Mobile Eye and Vision Clinic has hit the road to bring eye care to thousands of underserved Alabamians. Dr. Kent Daum, the clinics director, talks with a group at the official launch. (Michael Tomberlin/Alabama NewsCenter)

The Alabama Lions Mobile Eye and Vision Clinic is stocked with eyeglasses for people in the communities it visits. (Michael Tomberlin/Alabama NewsCenter)

Gunner Hewitt gets his picture made in front of the Alabama Lions Mobile Eye and Vision Clinic, which sports an image of Gunner on its side. (Michael Tomberlin/Alabama NewsCenter)

The Alabama Lions first Mobile Eye and Vision Clinic has hit the road to bring eye care to thousands of underserved Alabamians. (Michael Tomberlin/Alabama NewsCenter)

Daum said the clinic has made a dramatic difference. Instead of taking more than an hour a day to load and reload equipment into a van, Daum can now spend all his time in each community treating patients.

Weve had a very exciting first year, Daum said. Weve been out about 186 times. Almost every person we see needs glasses. About a third of our patients have diabetes and 15 percent have glaucoma or something related to it. Its such a privilege to have the opportunity to help these people.

As part of its efforts to provide lasting support for senior citizens and underprivileged people in rural areas, Alabama Lions Sight plans to establish a vision resource community that will include Lions Clubs, optometrists, ophthalmologists, hospitals and clinics statewide.

Were excited about really being able to reach out and move into the 21st century as far as providing eye care in the state of Alabama, Dean said. Through the mobile clinic, we are actually taking vision services to the communities. We are doing comprehensive eye exams, providing glasses on site and offering free transportation to those who need advanced eye care. Right now, were in 14 counties. Our ultimate goal is to be in every county in the state.

See more here:
Alabama Lions Sight takes services on the road with state's first Mobile Eye and Vision Clinic - Alabama NewsCenter

Read More...

Sight Simulator shows you what it’s like to be legally blind – CNET

March 1st, 2017 7:51 am

CNET's San Francisco headquarters as seen through the Sight Simulator's retinopathy filter on its highest setting.

What does the world look like if you're legally blind? A new interactive website lets you see through the eyes of those suffering from three conditions that impair sight.

The Sight Simulator is part of a campaign called See Now, aimed at increasing awareness of vision loss and calling for more Congressional funding to combat it in the US. The Simulator places filters that mimic the effects of cataracts, glaucoma and retinopathy on top of Google Street View images, enabling visitors to the site to move the slider and increase the severity of each ailment.

Looking at CNET's headquarters on the highest retinopathy setting showed me my familiar workplace blurry and obscured by dark splotches. With the glaucoma setting at its highest, I only saw a bright oval surrounded by black. The cataracts filter displayed a building so fuzzy it was hard to discern details.

"We believe when people experience what it would be like to lose their sight, from seeing what their own street looks like with poor vision, they will appreciate the problem in a way they never did before," Erin McCallum of the See Now campaign said in a statement. "Hopefully this will motivate many people to look after their own eye health and push them to take action to help prevent blindness in others."

The minimum setting on the site for all three conditions shows a view matching legal blindness. It's defined in the US as central visual acuity of 20/200 or less in the better eye with the best possible correction, and/or a visual field of 20 degrees or less, according to the American Foundation for the Blind.

"Legal blindness is not binary," the See Now site points out. "For most people with vision impairment, it's not a matter of seeing nothing versus seeing clearly. The reality is somewhere in between."

Yet four out of five people who are blind don't need to be, See Now asserts, saying a single doctor's visit or screening can prevent or cure the world's most common vision problems.

The See Now campaign was created in partnership with Prevent Blindness, an organization devoted to fighting blindness and saving sight, and is calling for increased federal funding to tackle eye health. More than 47,000 people have signed a petition asking Congress to dedicate $6.3 million to making eye care across the country more accessible.

This isn't the first time digital tools have helped the public view a health condition from a personal perspective.

A few years back, a campaign to increase awareness of the most common form of dementia put people in Facebook photos of fake events, aiming to give them a momentary sense of what the disease might feel like.

The cataracts filter, at its most severe setting, renders a familiar sight fuzziness.

CNET Magazine: Check out a sampling of the stories you'll find in CNET's newsstand edition.

Life, disrupted: In Europe, millions of refugees are still searching for a safe place to settle. Tech should be part of the solution. But is it? CNET investigates.

Read more:
Sight Simulator shows you what it's like to be legally blind - CNET

Read More...

New glasses provide eyesight for blind – Sentinel & Enterprise

March 1st, 2017 7:51 am

Yvonne Felix wears eSight electronic glasses and looks around Union Square during a visit to San Francisco. Felix was diagnosed with Stargardt s disease after being hit by a car age 7. AP PHOTO

SAN FRANCISCO (AP) -- Jeff Regan was born with underdeveloped optic nerves and had spent most of his life in a blur. Then four years ago, he donned an unwieldy headset made by a Toronto company called eSight.

Suddenly, Regan could read a newspaper while eating breakfast and make out the faces of his co-workers from across the room. He's been able to attend plays and watch what's happening on stage, without having to guess why people around him were laughing.

"These glasses have made my life so much better," said Regan, 48, a Canadian engineer who lives in London, Ontario.

The headsets from eSight transmit images from a forward-facing camera to small internal screens -- one for each eye -- in a way that beams the video into the wearer's peripheral vision. That turns out to be all that some people with limited vision, even legal blindness, need to see things they never could before. That's because many visual impairments degrade central vision while leaving peripheral vision largely intact.

Although eSight's glasses won't help people with total blindness, they could still be a huge deal for the millions of peoples whose vision is so impaired that it can't be corrected with ordinary lenses.

But eSight still needs to clear a few minor hurdles. Among them: proving the glasses are safe and effective for the legally blind. While eSight's headsets don't require the approval of health regulators -- they fall into the same low-risk category as dental floss -- there's not yet firm evidence of their benefits.

The headsets also carry an eye-popping price tag. The latest version of the glasses, released in mid-February, sells for about $10,000. While that's $5,000 less than its predecessor, it's still a lot for people who often have trouble getting high-paying jobs because they can't see.

Insurers won't cover the cost; they consider the glasses an "assistive" technology similar to hearing aids.

ESight CEO Brian Mech said the latest improvements might help insurers overcome their short-sighted view of his product. Mech argues that it would be more cost-effective for insurers to pay for the headsets, even in part, than to cover more expensive surgical procedures that may restore some sight to the visually impaired.

The latest version of ESight's technology, built with investments of $32 million over the past decade, is a gadget that vaguely resembles the visor worn by the blind "Star Trek" character Geordi La Forge, played by LeVar Burton.

The third-generation model lets wearers magnify the video feed up to 24 times, compared to just 14 times in earlier models. There's a hand control for adjusting brightness and contrast. The new glasses also come with a more powerful high-definition camera.

ESight believes that about 200 million people worldwide with visual acuity of 20/70 to 20/1200 could be potential candidates for its glasses. That number includes people with a variety of disabling eye conditions such as macular degeneration, diabetic retinopathy, ocular albinism, Stargardt's disease, or, like Regan, optic nerve hypoplasia.

So far, though, the company has sold only about 1,000 headsets, despite the testimonials of wearers who've become true believers.

Take, for instance, Yvonne Felix, an artist who now works as an advocate for eSight after seeing the previously indistinguishable faces of her husband and two sons for the first time via its glasses. Others, ranging from kids to senior citizens, have worn the gadgets to golf, watch football or just perform daily tasks such as reading nutrition labels.

ESight isn't the only company focused on helping the legally blind. Other companies working on high-tech glasses and related tools include Aira, Orcam, ThirdEye, NuEyes and Microsoft .

But most of them are doing something very different. While their approaches also involve cameras attached to glasses, they don't magnify live video. Instead, they take still images, analyze them with image recognition software and then generate an automated voice that describes what the wearer is looking at -- anything from a child to words written on a page.

See the original post here:
New glasses provide eyesight for blind - Sentinel & Enterprise

Read More...

Nicola McLean reveals she’s virtually BLIND in one eye just weeks after being bullied by cruel trolls mocking her … – The Sun

March 1st, 2017 7:51 am

The former glamour model had to get her husband Tom to have some glasses specially made and delivered into the house because of her condition

NICOLA McLean has revealed she is practically BLIND in one eye because of a rare condition.

The former glamour model was attacked by cruel trolls during her stint on Celebrity Big Brother earlier this year after she was seen covering one of her eyes when she argued with Kim Woodburn.

Splash News

And speaking exclusively to The Sun Online at a celebrity event on Tuesday night, Nicola revealed how her sight started to go just two months before entering the Big Brother house.

She said: I have always had bad eyesight in my left eye but my right eye has always been fine and then about two months before Big Brother I noticed my eyesight changing.

Now I can barely see out of this eye, Im talking barely see, Ive got a contact in it now.

Rex Features

Basically whats happened is, this right eye, I cant see out of but its also developed an adult squint, which is so rare.

Thats why I was so paranoid about it, as what would happen is, I would take the contact lens out, get in bed, then all the arguments would kick off so Id have to cover my eye.

Rex Features

I cant focus with it, so it wanders, without glasses or a contact it just wanders everywhere because I cant see out of it.

Nicola who was born with a squint in her left eye which was later rectified added her doctors think a potential cause could be pregnancy-related diabetes from when she had her two sons, Rocky and Striker.

While the diagnosis isnt clear yet, the 35-year-old added her squint is rectifiable, but it doesnt address her vision issues.

She said: The muscles at the back need to be tightened and that will rectify it being straight, but I still wont be able to see out of it.

A squint - known by its medical term strabismus - is where the eyes point in different directions.

The condition is common in kids, with one in 20 likely to have a squint.

And while they typically appear before the age of five, adults can be treated for the condition.

Squints that develop later in life are known as acquired squints.

They may be caused by the eye attempting to overcome a vision problem, such as short or long-sightedness.

In some cases they are genetic, while in most cases the cause is unknown.

Squints can be treated, with glasses, eye exercise and in some cases corrective surgery to tighten or move some of the eye muscles to change the eye's position.

Source: Moorfields Eye Hospital

"So we need to work out why the visions gone from being OK to so bad.

"Im OK because with a contact or my glasses its fine, mines not a lazy eye its a proper squint, so if I took my contact lens out now it would just wander.

"It can be corrected but its very, very rare to get an adult squint so thats what it was, I didnt want to be on tele with an eye wandering so Id cover it.

"If I dont cover the right one I cant see out of the left one, because when the right one shuts down the left one does, so I needed to cover the right to be able to see.

Fame Flynet

"It is quite bad but Ill be able to get it sorted."

Nicola's condition was never fully explained during her time on Celebrity Big Brother, and she also revealed her husband Tom Williams had to get some glasses especially made for her and have them sent in.

Fame Flynet

She continued: "It all happened so quickly before Big Brother.

"I had contacts but the air conditioning was making my contacts dry, so Tom had to get me glasses made and sent into the house, which is why I only started wearing them half way through."

Fame Flynet

Nicola's now in consultations with an eye hospital about her condition and finding a date to correct it.

She added: "We just need to know why its happened.

"The prescription to go from good to as bad as it is is not normal . Its quite concerning."

See original here:
Nicola McLean reveals she's virtually BLIND in one eye just weeks after being bullied by cruel trolls mocking her ... - The Sun

Read More...

Fasting Diet Reverses Diabetes in Mice – Voice of America

March 1st, 2017 7:50 am

A diet that mimics fasting temporarily put mice in a starvation state, reversing diabetes in the animals, according to a new study. The diet was also shown to reduce the risk factors in people with pre-diabetes

Research by investigators at the University of Southern California showed the special, fasting-mimicking diet triggers the development of insulin-producing cells in mice with diabetes. The study was published in the journal Cell.

In humans, an earlier study of the diet reduced the risk factors of diabetes, such as elevated blood sugar, in people who were headed toward development of the disease. An article on the diet in humans appeared in Science Translational Medicine.

In both Type 1 diabetes and in the later stages of Type 2 diabetes, the beta cells of the pancreas are destroyed. But the authors said the diet appears to "reboot" the body, switching on genes that trigger the release of stem cells, master cells responsible for organ development.

More than fasting required

However, fasting alone is not the key to restoring insulin levels. Scientists said refeeding after the brief starvation diet, with specially calibrated nutrients, is critical to kickstarting the production of new beta cells.

FILE - A woman fills a syringe as she prepares to give herself an injection of insulin.

The process of stem cell activation is the same as seen in embryos to stimulate organ growth, according to gerontology professor Valter Longo, the director of USC's Longevity Institute and senior author of both studies. He said the fasting-mimicking diet can be used to reprogram cells without any genetic alterations.

"So basically the system is using some of the same program that we use during embryonic and fetal development to regenerate the pancreas once the food comes back around," he said. "And that's the trick. It's not so much the starvation. It's really the combination of the starvation and the refeeding." And, he stressed, "the refeeding's got to be a high-nourishment one."

Study participants put on the high-fat, low-calorie, low-protein diet consumed between 800 and 1,100 calories daily for five days in a row each month for three months. After each fast, they were refed with nutrient-rich foods.

Researchers found fasting triggered the production of a protein called Ngn3, which generated new, healthy beta cells that secreted insulin. They saw production of insulin in a dish in pancreatic cells extracted from mice and from healthy human donors and patients with both types of diabetes.

Scientists found the diet replaced damaged insulin-producing cells with new functioning ones in mice placed on the diet for four days.

Heart disease, cancer risks

The investigators have also amassed evidence that the fasting-mimicking diet reduces the risk of age-related diseases, including heart disease and cancer. It may also hold benefits for people with multiple sclerosis, said researchers.

FILE - A woman who suffers from diabetes is seen walking on a treadmill as part of an exercise program to help control the disease.

But Longo said people with diabetes should not try the diet at home yet because it can drop blood sugar to perilously low levels if they don't know what they are doing. "We warn people that, particularly [for people with] Type 1 or patients that inject themselves with insulin, it can be very risky or even lethal," Longo cautioned.

He said investigators were poised to begin larger human clinical trials of the fasting-mimicking diet in the next six months.

View original post here:
Fasting Diet Reverses Diabetes in Mice - Voice of America

Read More...

Youth with type 2 diabetes develop complications more often than type 1 peers – National Institutes of Health (press release)

March 1st, 2017 7:50 am

Medscape
Youth with type 2 diabetes develop complications more often than type 1 peers
National Institutes of Health (press release)
Teens and young adults with type 2 diabetes develop kidney, nerve, and eye diseases as well as some risk factors for heart disease more often than their peers with type 1 diabetes in the years shortly after diagnosis. The results are the latest ...
72% of Youth With Type 2 Diabetes Have ComplicationsMedscape
Youth With Type 2 Diabetes Often Face ComplicationsEveryday Health (blog)
New Research: More Young People Suffer Complications From DiabetesCBS Local
CU Anschutz Today (press release) -Nursing Times -MedicalResearch.com (blog)
all 10 news articles »

More here:
Youth with type 2 diabetes develop complications more often than type 1 peers - National Institutes of Health (press release)

Read More...

Page 1,060«..1020..1,0591,0601,0611,062..1,0701,080..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick